Collagen induced MMP-2 activation in human breast cancer.
Matrix metalloproteinase-2 (MMP-2), a zymogen requiring proteolytic activation for catalytic activity, has been implicated broadly in the invasion and metastasis of many cancer model systems, including human breast cancer (HBC). MMP-2 has been immunolocalized to carcinomatous human breast, where the degree of activation of MMP-2 correlates well with tumor grade and patient prognosis. Using Matrigel assays, we have stratified HBC cell lines for invasiveness in vitro, and compared this to their potential for metastatic spread in nude mice. HBC cell lines expressing the mesenchymal marker protein vimentin were found to be highly invasive in vitro, and tended to form metastases in nude mice. We have further discovered that culture on collagen-I gels (Vitrogen; Vg) induces MMP-2-activator in highly invasive but not poorly invasive HBC cell lines. As seen for other MMP-2-activator inducing regimens, this induction requires protein synthesis and an intact MMP-2 hemopexin-like domain, appears to be mediated by a cell surface activity, and can be inhibited by metalloproteinase inhibitors. The induction is highly specific to collagen I, and is not seen with thin coatings of collagen I, collagen IV, laminin, or fibronectin, or with 3-dimensional gels of laminin, Matrigel, or gelatin. This review focuses on collagen I and MMP-2, their localization and source in HBC, and their relationship(s) to MMP-2 activation and HBC metastasis. The relevance of collagen I in activation of MMP-2 in vivo is discussed in terms of stromal cell: tumor cell interaction for collagen I deposition, MMP-2 production, and MMP-2-activation. Such cooperativity may exist in vivo for MMP-2 participation in HBC dissemination. A more complete understanding of the regulation of MMP-2-activator by type I collagen may provide new avenues for improved diagnosis and prognosis of human breast cancer.
Thompson
E W
EW
Vincent T. Lombardi Cancer Research Center, Georgetown University Medical Center, Washington, DC 20007.
Yu
M
M
Bueno
J
J
Jin
L
L
Maiti
S N
SN
Palao-Marco
F L
FL
Pulyaeva
H
H
Tamborlane
J W
JW
Tirgari
R
R
Wapnir
I
I
D000595:Amino Acid Sequence; D001485:Basement Membrane / Q000378:metabolism / Q000473:pathology; D001943:Breast Neoplasms / Q000201:enzymology*; D003094:Collagen / Q000494:pharmacology*; D003238:Connective Tissue / Q000473:pathology; D004338:Drug Combinations; D004789:Enzyme Activation / Q000187:drug effects; D004792:Enzyme Precursors / Q000378:metabolism; D005109:Extracellular Matrix / Q000378:metabolism; D005347:Fibroblasts / Q000473:pathology; D018093:Gelatinases / Q000187:drug effects*; D006801:Humans; D016023:Integrins / Q000502:physiology; D007797:Laminin; D020778:Matrix Metalloproteinase 2; D008666:Metalloendopeptidases / Q000187:drug effects*; D008969:Molecular Sequence Data; D009361:Neoplasm Invasiveness / Q000503:physiopathology*; D009363:Neoplasm Proteins / Q000378:metabolism*; D011509:Proteoglycans; D038981:Receptors, Collagen; D015398:Signal Transduction; D014407:Tumor Cells, Cultured
D004338:Drug Combinations; D004792:Enzyme Precursors; D016023:Integrins; D007797:Laminin; D009363:Neoplasm Proteins; D011509:Proteoglycans; D038981:Receptors, Collagen; C059485:matrigel; D003094:Collagen; D018093:Gelatinases; D008666:Metalloendopeptidases; D020778:Matrix Metalloproteinase 2